Analyst Price Target is $3.17
▲ +1,467.66% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Evelo Biosciences in the last 3 months. The average price target is $3.17, with a high forecast of $5.00 and a low forecast of $2.00. The average price target represents a 1,467.66% upside from the last price of $0.20.
Current Consensus is
The current consensus among 4 polled investment analysts is to hold stock in Evelo Biosciences. This rating has held steady since October 2022, when it changed from a Buy consensus rating.
Evelo Biosciences, Inc. operates as a clinical stage biotechnology company, which engages in the development of orally delivered investigational medicines. Its portfolio includes EDP1066 and EDP1815 for the treatment of inflammatory diseases, EDP2939 for inflammation, and EDP1908 for oncology. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA.